NSABP-B64: EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease

Title
EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
Principal Investigator
Jiang, Bei
Phase
NA
Age Group
Adult
Applicable Disease Sites
Breast Cancer
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Kaitlyn Hager
Research Nurse
Email:

View on ClinicalTrials.gov